CD4 and neoplasm: By simultaneously depleting the glutathione (GSH) and boosting HIFU-induced tumor ICD, MBPs can modulate the tumor immune microenvironment by inducing dendritic cell (DC) maturation and promoting CD8+ and CD4+ T cell activation, thereby inhibiting tumor growth and lung metastasis (Figure 2D–F).